Journal · Updated 2026-08-11
HealthRX Review 2026: $99 Semaglutide With a Term Ladder and No Monthly Option
By the GLP1ProviderFinder Research Desk · Medically reviewed by Dr. A. Goher, MD · Last reviewed 2026-08-11 · How we verify
Short answer — August 2026
HealthRX publishes a two-rung ladder, flat at every dose: semaglutide at ninety-nine dollars a month on the twelve-month plan and one thirty-three on the three-month; tirzepatide at one seventy-nine and two-oh-nine on the same terms — billed monthly, per July 2026 first-party captures (reported status, our checkout capture pending). The structural quirk that defines it: no month-to-month option exists at all — three months is the minimum door — which keeps HealthRX out of our no-commitment rankings entirely while placing it squarely on the ninety-nine-dollar committed semaglutide floor alongside bmiMD and Trimi, and one rung behind the one thirty-nine tirzepatide leaders on the annual tier. The right frame: a committed buyer's program, priced accordingly, with the commitment stated on the label rather than discovered at checkout.
The shape: minimum three months, maximum clarity
Everything about the ladder is the honest kind of simple — same price at every dose (dose-anchoring neutralized), no membership line, term-anchored rates that say so. The absence of a monthly plan is a real filter, not a flaw: it screens out the try-it-a-month buyer by design, and it means HealthRX's cheapest figures compare against bmiMD's twelve-month tiers, not against anyone's monthly rate. That comparison, in words: on semaglutide the two programs tie at ninety-nine, both billed monthly, with bmiMD offering the monthly escape hatch HealthRX doesn't; on tirzepatide bmiMD's one thirty-nine beats HealthRX's one seventy-nine on the annual tier outright — a forty-dollar monthly gap that makes HealthRX a semaglutide story far more than a tirzepatide one. The three-month rungs (one thirty-three, two-oh-nine) exist mainly as the shortest test drive the program sells.
The checks, and the verdict
Same two as everywhere in this tier: extract the pharmacy name at intake and run the fifteen-minute verification, and pin the mid-term exit mechanics in writing — what leaving a twelve-month plan in month five costs, and whether the term rate is locked. Then the placement: for a semaglutide buyer certain of the year, HealthRX is a co-champion at ninety-nine with clean flat-dose structure; for one uncertain, bmiMD's identical rate with a monthly option dominates; for a tirzepatide buyer, the one seventy-nine annual rate is beatable at bmiMD and NexLife (one thirty-nine) and the whole no-commitment tier exists at nearly the same price without the term. A program this legible is easy to place — which is itself the compliment.
Questions people ask
How much does HealthRX cost per month?
Semaglutide: $99 on the twelve-month plan, $133 on the three-month. Tirzepatide: $179 and $209 on the same terms. Same price at every dose, billed monthly, no membership — and no month-to-month plan exists; three months is the minimum commitment. Reported status from July 2026 first-party captures.
Is HealthRX's $99 semaglutide legit?
It's a real published twelve-month-plan rate (July 2026 captures), co-holding the committed floor with bmiMD and Trimi — with the standard homework attached: get the pharmacy name at intake and verify it, and pin the mid-term exit terms in writing. The rate requires the year; the shortest available commitment is three months at $133.
HealthRX vs bmiMD — which is cheaper?
Semaglutide: tie at $99 on twelve-month plans, both billed monthly — bmiMD wins on flexibility (it offers a $129 monthly option; HealthRX has none). Tirzepatide: bmiMD wins outright, $139 vs $179 on the annual tier. HealthRX is a semaglutide-first choice for committed buyers.
This article is pricing research, not medical advice. Verify figures at the provider's checkout. Nothing here is medical advice.